NEW YORK (GenomeWeb news) – Scientists at Newcastle University will study a panel of Horizon Discovery's mutant and normal X-MAN cancer models for imaging biomarkers that can identify cancer genes within tumors, the university said today.
The goal of the research, which is set to begin this month, is to identify markers that will lead to targeted and personalized drug therapies.
Horizon developed the X-MAN models using its Genesis gene engineering technology.
While recent medical advances have enabled development of targeted therapies for cancer treatment, Newcastle University and Cancer Research UK researcher Herbie Newell said in a statement, "these therapies require tests or biomarkers for effective clinical use in order to match the right drug to the right patient which this collaboration will seek to address."
Financial terms of the agreement were not released.